Xylem Analysts Lower Their Forecasts After Q4 Results

Core Viewpoint - Xylem Inc reported strong fourth-quarter earnings, exceeding analyst expectations in both earnings per share and sales figures [1][2]. Financial Performance - The company posted quarterly earnings of $1.42 per share, surpassing the analyst consensus estimate of $1.41 per share [1]. - Quarterly sales reached $2.397 billion, exceeding the analyst consensus estimate of $2.374 billion [1]. - For FY2026, Xylem projects adjusted EPS between $5.35 and $5.56, slightly below market estimates of $5.56 [1]. - The company anticipates sales of $9.100 billion to $9.200 billion, compared to expectations of $9.331 billion [1]. Management Commentary - CEO Matthew Pine highlighted the strong fourth quarter as part of a year of solid execution and transformation, achieving record full-year revenue, adjusted EBITDA margin, and adjusted EPS [2]. - Pine noted broad-based demand across major end markets and healthy organic revenue and orders growth, providing momentum heading into 2026 [2]. Stock Performance and Analyst Ratings - Following the earnings announcement, Xylem shares dipped 2.1% to trade at $126.24 [2]. - Barclays analyst William Grippin maintained an Overweight rating on Xylem but lowered the price target from $166 to $156 [4]. - RBC Capital analyst Deane Dray maintained an Outperform rating while reducing the price target from $176 to $162 [4].